FDA Seeks New Power Over Drug Ads in 2027 Budget
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- U.S. Food and Drug Administration is seeking new powers to hold companies accountable for misleading direct‑to‑consumer drug ads, according to a Fierce Pharma report.
- U.S. Food and Drug Administration included a request for these powers in its 2027 budget proposal, citing the need for additional authorities to address unfair and confusing advertising.
- U.S. Food and Drug Administration acts on a last‑year Trump order that demanded balanced drug benefit‑risk information in DTC ads, fueling its recent enforcement push.
- U.S. Food and Drug Administration sent letters alleging violations of federal pharma marketing rules to Bristol Myers Squibb, Eli Lilly and Novartis after the presidential order.
- U.S. Food and Drug Administration continues to issue letters to firms it accuses of breaking DTC advertising rules, indicating ongoing enforcement activity.
Why it matters: Pharma companies will face stricter oversight and possible penalties as the FDA seeks statutory authority to enforce balanced drug advertising, while patients gain clearer, less misleading information about medication risks and benefits. The budget request signals a shift from voluntary compliance to enforceable rules.
